Moxonidine

How to order Moxonidine

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Moxonidine on Prescriptsy

Moxonidine is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Moxonidine is a centrally-acting antihypertensive medicine used to treat mild to moderate essential hypertension (high blood pressure without an identifiable underlying cause).

It works by stimulating imidazoline I1 receptors in the brainstem, which reduces sympathetic nervous system activity and lowers blood pressure.

Moxonidine is available as 200 microgram and 400 microgram tablets and is classified as a prescription-only medicine (POM) in the United Kingdom.

It may be prescribed when first-line antihypertensive agents have not achieved adequate blood pressure control or when they cause intolerable side effects.

Hypertension is one of the most significant modifiable risk factors for cardiovascular disease, stroke and chronic kidney disease.

In the United Kingdom, approximately one in three adults has high blood pressure, and many remain undiagnosed.

The 2019 NICE guideline on hypertension (NG136) recommends a stepped approach to treatment, starting with ACE inhibitors or ARBs, calcium channel blockers and thiazide-like diuretics.

Moxonidine occupies a role later in the treatment pathway, typically as add-on therapy.

This page provides a comprehensive clinical overview of moxonidine, including how it works, dosage, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about moxonidine

• Moxonidine is a prescription-only medicine and should be used under medical supervision.
• Do not stop moxonidine abruptly. Sudden withdrawal may cause a rebound rise in blood pressure.
• Moxonidine must not be used in patients with severe heart failure (NYHA class III or IV), as a clinical trial showed increased mortality.
• Dry mouth, dizziness and fatigue are the most common side effects.
• Dose adjustment is required in moderate renal impairment. Not recommended in severe renal impairment.

Understanding hypertension and its treatment in the UK

Blood pressure is the force exerted by circulating blood on the walls of the arteries.

It is expressed as two numbers: systolic (the pressure when the heart contracts) and diastolic (the pressure when the heart relaxes).

The NHS defines high blood pressure as a clinic reading consistently at or above 140/90 mmHg or an ambulatory/home average at or above 135/85 mmHg.

Untreated hypertension increases the risk of heart attack, stroke, heart failure, chronic kidney disease and vascular dementia.

The NICE guideline on hypertension (NG136) recommends a staged approach to treatment.

Step 1 involves lifestyle modification (dietary changes, salt reduction, regular exercise, weight management, reduced alcohol intake) and pharmacological therapy with an ACE inhibitor or angiotensin receptor blocker (ARB), or a calcium channel blocker for people of Black African or Caribbean descent or those over 55.

Step 2 adds a second agent, and step 3 combines three agents.

Step 4 addresses resistant hypertension, defined as blood pressure that remains above target despite optimal doses of three agents.

At this stage, NICE recommends considering spironolactone (if potassium is 4.5 mmol/L or below), an alpha-blocker (doxazosin), or a beta-blocker.

Centrally-acting agents such as moxonidine are not specifically recommended in NG136 but are recognised in clinical practice as additional options.

How moxonidine works: mechanism of action

Moxonidine belongs to a class of medicines known as centrally-acting antihypertensives.

These drugs act within the central nervous system, specifically in the brainstem, to reduce sympathetic outflow to the heart and blood vessels.

The sympathetic nervous system is part of the autonomic nervous system and plays a key role in regulating blood pressure.

Excessive sympathetic activity is a recognised contributor to essential hypertension.

Moxonidine is a selective agonist of imidazoline I1 receptors located in the rostral ventrolateral medulla (RVLM) of the brainstem.

Activation of these receptors inhibits sympathetic tone, leading to reduced peripheral vascular resistance and a fall in blood pressure. Heart rate is mildly reduced.

Unlike clonidine, an older centrally-acting agent that primarily stimulates alpha-2 adrenergic receptors, moxonidine has high selectivity for imidazoline I1 receptors and low affinity for alpha-2 receptors.

This selectivity is clinically important: it means moxonidine causes less sedation, less dry mouth and less rebound hypertension on withdrawal compared with clonidine, although gradual dose reduction is still recommended when discontinuing treatment.

Beyond its blood pressure-lowering effects, moxonidine may have additional metabolic benefits.

Some studies have suggested improvements in insulin sensitivity and glucose metabolism, and a reduction in sympathetic overdrive that characterises metabolic syndrome.

However, these effects are not the primary indication for prescribing moxonidine, and the evidence is not sufficient to support its use for metabolic outcomes alone.

Pharmacokinetics

Moxonidine is rapidly and almost completely absorbed after oral administration, with a bioavailability of approximately 88 percent. Peak plasma concentrations are reached within about 1 hour.

The plasma elimination half-life is 2 to 3 hours, which is relatively short.

However, the antihypertensive effect persists for up to 24 hours, possibly due to sustained receptor occupancy in the brainstem.

Moxonidine is excreted primarily by the kidneys, with approximately 50 to 75 percent of the dose recovered unchanged in the urine.

This renal excretion profile necessitates dose reduction in patients with moderate renal impairment and contraindicates use in severe renal impairment.

Clinical evidence for moxonidine

The efficacy of moxonidine in lowering blood pressure has been demonstrated in multiple randomised controlled trials.

In placebo-controlled studies, moxonidine 200 to 600 micrograms daily reduced systolic blood pressure by 10 to 20 mmHg and diastolic blood pressure by 7 to 12 mmHg.

Active-comparator trials have shown blood pressure reductions comparable to those achieved with ACE inhibitors, calcium channel blockers and beta-blockers.

A meta-analysis of clinical trials reported that moxonidine was associated with a significantly lower incidence of dry mouth compared with clonidine, supporting its improved tolerability profile.

The MOXCON (MOXonidine CONgestive heart failure) trial is an important safety study.

This double-blind, placebo-controlled trial evaluated sustained-release moxonidine in patients with chronic heart failure (NYHA class II to IV).

The trial was terminated prematurely because the moxonidine group experienced higher rates of mortality, sudden death and worsening heart failure compared with placebo.

This finding established a clear contraindication for moxonidine in moderate to severe heart failure and serves as an essential safety consideration for prescribers.

Moxonidine compared with other antihypertensives

The UK antihypertensive armamentarium includes ACE inhibitors (ramipril, lisinopril, enalapril), ARBs (losartan, candesartan, valsartan, irbesartan), calcium channel blockers (amlodipine, nifedipine), thiazide-like diuretics (indapamide, chlorthalidone), beta-blockers (bisoprolol, atenolol), alpha-blockers (doxazosin) and mineralocorticoid receptor antagonists (spironolactone).

These classes form the mainstay of NICE-recommended stepped therapy.

Moxonidine occupies a distinct niche as a centrally-acting agent with a mechanism of action different from all the above classes.

It may be considered in patients who have not reached blood pressure targets on first-line and second-line agents, who experience intolerable side effects from other classes, or who have sympathetically mediated hypertension with features such as tachycardia, anxiety, or sweating.

It may also be useful as adjunctive therapy in resistant hypertension, although spironolactone and doxazosin are generally preferred at step 4 according to NICE NG136.

Compared with clonidine, moxonidine offers better tolerability with less sedation, less dry mouth and a lower risk of rebound hypertension.

Compared with methyldopa (another centrally-acting agent used primarily in pregnancy-related hypertension), moxonidine has a cleaner side-effect profile but is not recommended in pregnancy.

Dosage and administration

The starting dose of moxonidine is 200 micrograms once daily, taken in the morning with or without food. Swallow the tablet whole with water.

If blood pressure control is inadequate after 3 weeks, the dose may be increased to 400 micrograms daily, given as a single dose or divided into two doses (morning and evening).

After a further 3 weeks, a further increase to a maximum of 600 micrograms daily in two divided doses may be considered.

The maximum single dose is 400 micrograms.

Take moxonidine at the same time each day for consistent blood pressure control.

If you miss a dose, take it as soon as you remember unless it is close to the time of the next dose. Do not double the dose.

Do not stop moxonidine suddenly. If discontinuation is needed, reduce the dose gradually over 2 weeks under medical supervision to avoid rebound hypertension.

In moderate renal impairment (GFR 30 to 60 mL/min), the starting dose is 200 micrograms daily and the maximum is 400 micrograms daily.

Moxonidine is not recommended for patients with severe renal impairment (GFR below 30 mL/min) or those on haemodialysis.

No specific dose adjustment is required in elderly patients, although prescribers should account for age-related decline in renal function.

Side effects of moxonidine

Common side effects

Dry mouth is the most frequently reported side effect, affecting approximately 10 to 15 percent of patients. It is usually mild and less pronounced than with clonidine.

Headache, dizziness and fatigue occur in approximately 5 to 10 percent of patients and are most common during the initial weeks of treatment or after dose increases.

These effects generally improve with continued use.

Less common side effects

Nausea, sleep disturbance (insomnia or drowsiness), asthenia, skin rash and peripheral oedema have been reported.

Bradycardia and hypotension may occur, particularly at higher doses or in combination with other blood pressure-lowering medicines.

If you experience fainting, a very slow heartbeat, or persistent dizziness, seek medical advice.

Rare side effects

Angioedema (swelling of the face, lips, tongue or throat) is a rare but potentially serious reaction requiring immediate medical attention. Call 999 if you develop sudden swelling of the face or throat or have difficulty breathing.

Rebound hypertension

If moxonidine is stopped suddenly, blood pressure may rise sharply (rebound hypertension). Symptoms can include severe headache, palpitations, anxiety and agitation. Always taper the dose gradually over 2 weeks under medical supervision.

When to seek urgent advice

Contact your GP or call NHS 111 if you experience persistent dizziness, fainting episodes, a very slow heartbeat, unusual swelling, or persistent side effects. Call 999 in an emergency. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk.

Warnings and precautions

Contraindications

Moxonidine must not be used in patients with sick sinus syndrome, sino-atrial block, second- or third-degree atrioventricular block, resting bradycardia (below 50 bpm), severe heart failure (NYHA III or IV), severe coronary artery disease or unstable angina, severe hepatic impairment, severe renal impairment (GFR below 30 mL/min), hereditary angioedema, or hypersensitivity to moxonidine or any excipient.

Heart failure

The MOXCON trial demonstrated increased mortality in patients with heart failure taking moxonidine.

It must not be used in NYHA class III or IV heart failure and should be used with caution in class II.

If heart failure develops or worsens during treatment, moxonidine should be discontinued gradually.

Driving and operating machinery

Moxonidine may cause drowsiness and dizziness, particularly at the start of treatment. Do not drive or operate heavy machinery until you know how the medicine affects you. If you experience persistent drowsiness, discuss this with your prescriber.

Drug interactions

Moxonidine may enhance the effects of other antihypertensive agents.

Blood pressure and heart rate should be monitored when combining moxonidine with beta-blockers, ACE inhibitors, ARBs, calcium channel blockers or diuretics.

Avoid concomitant use with tricyclic antidepressants, which may reduce the antihypertensive effect. Benzodiazepines and other CNS depressants may increase sedation when used with moxonidine.

If moxonidine and a beta-blocker need to be discontinued simultaneously, stop the beta-blocker first, followed by moxonidine several days later, to avoid rebound effects.

Pregnancy and breastfeeding

Moxonidine should not be used during pregnancy unless the benefit outweighs the risk. There are limited human data.

Methyldopa, labetalol and nifedipine are the preferred antihypertensive agents in pregnancy as recommended by NICE guideline NG133.

Moxonidine is excreted in animal milk and breastfeeding is not recommended during treatment.

How to get moxonidine in the UK

Moxonidine is a prescription-only medicine available on the NHS. Your GP or hospital specialist can prescribe it.

It is also available through authorised online prescribers registered with the GPhC.

The standard NHS prescription charge of 9.90 pounds per item applies in England; prescriptions are free in Scotland, Wales and Northern Ireland.

Lifestyle advice for managing blood pressure

Medication is most effective when combined with lifestyle modifications. Reduce dietary salt to less than 6 g per day.

Eat a balanced diet rich in fruit, vegetables, whole grains and low-fat dairy (the DASH diet pattern is well supported by evidence).

Maintain a healthy weight, as losing even a small amount of weight can meaningfully reduce blood pressure.

Aim for at least 150 minutes of moderate-intensity physical activity per week. Limit alcohol to no more than 14 units per week.

If you smoke, stopping is one of the most important steps you can take for cardiovascular health.

Attend regular blood pressure checks and follow your prescriber's advice on medication and monitoring.

Sources

• Moxonidine film-coated tablets, Summary of Product Characteristics (EMC)
• Moxonidine, British National Formulary (BNF)
• NICE NG136: Hypertension in adults
• High blood pressure, NHS
• MHRA Yellow Card Scheme